Thalidomide-associated hepatitis: a case report |
| |
Authors: | Fowler R Imrie K |
| |
Affiliation: | Department of Medical Oncology and Hematology, Toronto-Sunnybrook Regional Cancer Centre, Faculty of Medicine, University of Toronto, Toronto, Canada. |
| |
Abstract: | We report a case of hepatitis in a 58-year-old woman being treated with thalidomide for end-stage plasma cell leukemia. The patient had a medical history including chronic stable hepatitis C infection. At diagnosis there was a severe anemia, thrombocytopenia, hypercalcemia, IgG paraproteinemia, peripheral blood myeloma cells, and a marrow plasmacytosis with lytic bony lesion. The disease was refractory to standard chemotherapy, and she was treated with oral thalidomide. Within 1 week she became jaundiced and developed a marked transaminitis. This promptly resolved upon cessation of thalidomide alone. Thalidomide has recently enjoyed renewed interest as a treatment in many disorders, including plasma cell leukemia. To our knowledge, this is the first reported case of thalidomide-associated hepatotoxicity. Although the mechanism of its actions on the liver are uncertain, it is possible that thalidomide acts as a direct hepatotoxin or as an immuno-modulator, altering the activity of chronic viral hepatitis. We present this case to increase awareness of a new potential side effect of thalidomide as its clinical indications expand. |
| |
Keywords: | thalidomide hepatitis liver multiple myeloma leukemia |
本文献已被 PubMed 等数据库收录! |
|